NEW ORLEANS — Apremilast 30 mg significantly improved genital psoriasis severity and quality of life compared with placebo in the first trial to study an oral treatment for this indication, according to a presentation here.In the multicenter, double-blind, phase 3 DISCREET study, researchers analyzed the efficacy of apremilast in patients with genital psoriasis.
Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.Tremfya (guselkumab, Janssen Biotech) is the first and only fully human selective interleukin (IL)-23 approved in the United States for adults with moderate to severe plaque
NEW ORLEANS — Izokibep, a novel interleukin-17 inhibitor, has shown dramatic responses in hidradenitis suppurativa treatment in an early phase 2 study, according to a speaker at the American Academy of Dermatology Annual Meeting.“[Hidradenitis suppurativa (HS)] is a horrible, horrible disease with a high disease burden. It’s extremely disruptive to anyone’s personal
NEW ORLEANS — Patients with psoriasis who had suboptimal results with prior interleukin-17 therapy experienced beneficial results with risankizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.
“Within the real world, patients with residual disease really want to switch onto more effective therapy,” Richard B. Warren, MBChB, PhD, of the
NEW ORLEANS — Advancements in atopic dermatitis treatment have allowed prescribers and patients to choose between various options, according to a presenter at the American Academy of Dermatology Annual Meeting.
“This is an incredible time for atopic dermatitis,” Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of